Base Therapeutics (shanghai) Co., Ltd.

This early-phase study tests a new treatment called NK510 (a type of immune cell therapy) combined with PD-1 inhibitors for people with advanced non-small cell lung cancer that has come back or not responded to prior treatments. The trial includes two ways to give the therapy: th…

This early-phase study tests an experimental cell therapy called NK521 in 18 adults with advanced solid tumors (like liver, stomach, or ovarian cancer) that have not responded to at least two prior treatments and have caused malignant ascites—a painful buildup of fluid in the bel…